Nkarta studies show complete remissions in patients with blood cancers

A colorized scanning electron micrograph of a natural killer cell from a human donor.

image

karta said Monday that two experimental, off-the-shelf treatments, both made from engineered natural killer cells, induced complete responses in patients with advanced forms of blood cancer. The results marked the first reveal of clinical data from its research programs.

In one of the clinical trials, three of five patients with acute myeloid leukemia achieved complete remissions. Two of those patients showed no evidence of residual disease — the best response possible following treatment with the highest-tested dose of the Nkarta engineered natural killer, or NK, cells.

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free.